Bioanalysis · 2013 · 38 citations · 7 references
PharmacyImmunologyPharmaceuticsClinical ImmunologyImmunotechnologyMonoclonal AntibodiesAntibody CharacterizationAntibody ConjugatesAntibody-drug ConjugatesBioanalytical Method ValidationEnzyme-linked Immunosorbent AssayImmunoassay AnalysisAnalytical Characterization Of ConjugatesAntibodiesAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate LinkersAntibody-drug LinkersAssayBioanalytical MethodologyMonoclonal Antibody Recognition
BACKGROUND: Immunogenicity testing is an important component of clinical development for large-molecule biotherapeutics. New complex types of large molecules, such as antibody-drug conjugates (ADCs), require careful evaluation of the testing strategy and bioanalytical assays used to monitor the development of antitherapeutic antibodies. RESULTS: An electrochemiluminescence-based immunoassay for the detection and epitope characterization of anti-ADC antibodies was validated. Using this assay format, antibodies directed against the monoclonal antibody and linker-drug components of the ADC were successfully detected in a multiple-dose rat toxicity study. CONCLUSION: Immunogenicity assays incorporating epitope determination may provide additional information about the characteristics of induced antitherapeutic antibodies, including the magnitude and timing of the various types of antibody responses.
7
Anthony R. Mire‐Sluis, Yu Chen Barrett, Viswanath Devanarayan et al. · Journal of Immunological Methods · 2004 · 621 citations
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher, Ravi Chari · Clinical Cancer Research · 2011 · 422 citations
Pharmacy, Oncology, Pharmaceutics +17
Judith A. James, R. Hal Scofield, John B. Harley · The Journal of Experimental Medicine · 1995 · 340 citations · Full text
Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate Biotherapeutics
Surinder Kaur, Keyang Xu, Ola M. Saad et al. · Bioanalysis · 2013 · 232 citations
Pharmacy, Oncology, Pharmacology +17